GTBP Stock Analysis: Buy, Sell, or Hold?
GTBP - GT Biopharma Inc. Common Stock
$0.29
-0.01 (-3.87%)
▼
5d:
-5.69%
30d:
-1.74%
90d:
-34.75%
HOLD
LOW Confidence
Analysis Updated: Aug 28, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When GTBP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GTBP shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: GTBP shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: GTBP is currently trading at $0.29, which is considered oversold relative to its 30-day fair value range of $0.29 to $0.32.
Technical Outlook: Technically, GTBP is in a downtrend. Immediate support is located at $0.27, while resistance sits at $0.32. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: GTBP scores 64/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $3.00 (+900.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GTBP is in a downtrend. Immediate support is located at $0.27, while resistance sits at $0.32. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: GTBP scores 64/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $3.00 (+900.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.29 -
$0.32
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (64/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.9%)
- BULLISH: Trading 900.0% below Wall St target ($3.00)
- BULLISH: Bottoming setup score 64/100 — corrected, stabilizing, and turning up
- CAUTION: Recommendation downgraded due to -5.7% 5-day decline
Trading Range Analysis
30-Day Trading Range
$0.29 -
$0.32
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.27
Resistance Level
$0.32
Current Trend
Downtrend
Technical data as of
Aug 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.94
Wall Street Target
$3.00
(+900.0%)
Share & Embed Analysis
Last updated: August 31, 2026 12:54 PM ET
Data refreshes hourly during market hours. Next update: 1:54 PM
Data refreshes hourly during market hours. Next update: 1:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GTBP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 59 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 29 SELL |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 38 SELL |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
